Logo image of ARWR

ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock Fundamental Analysis

NASDAQ:ARWR - Nasdaq - US04280A1007 - Common Stock - Currency: USD

13.25  -0.09 (-0.67%)

After market: 13.25 0 (0%)

Fundamental Rating

2

Overall ARWR gets a fundamental rating of 2 out of 10. We evaluated ARWR against 568 industry peers in the Biotechnology industry. ARWR may be in some trouble as it scores bad on both profitability and health. ARWR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ARWR has reported negative net income.
ARWR had a negative operating cash flow in the past year.
In the past 5 years ARWR always reported negative net income.
In the past 5 years ARWR reported 4 times negative operating cash flow.
ARWR Yearly Net Income VS EBIT VS OCF VS FCFARWR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

Looking at the Return On Assets, with a value of -63.11%, ARWR is doing worse than 61.44% of the companies in the same industry.
ARWR has a worse Return On Equity (-1216.44%) than 83.63% of its industry peers.
Industry RankSector Rank
ROA -63.11%
ROE -1216.44%
ROIC N/A
ROA(3y)-34.95%
ROA(5y)-28.18%
ROE(3y)-147.71%
ROE(5y)-99.18%
ROIC(3y)N/A
ROIC(5y)N/A
ARWR Yearly ROA, ROE, ROICARWR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

ARWR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARWR Yearly Profit, Operating, Gross MarginsARWR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

3

2. Health

2.1 Basic Checks

ARWR does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARWR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ARWR has been increased compared to 5 years ago.
The debt/assets ratio for ARWR is higher compared to a year ago.
ARWR Yearly Shares OutstandingARWR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ARWR Yearly Total Debt VS Total AssetsARWR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -2.81, we must say that ARWR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ARWR (-2.81) is comparable to the rest of the industry.
ARWR has a Debt/Equity ratio of 7.75. This is a high value indicating a heavy dependency on external financing.
ARWR's Debt to Equity ratio of 7.75 is on the low side compared to the rest of the industry. ARWR is outperformed by 83.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 7.75
Debt/FCF N/A
Altman-Z -2.81
ROIC/WACCN/A
WACC10.04%
ARWR Yearly LT Debt VS Equity VS FCFARWR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M

2.3 Liquidity

ARWR has a Current Ratio of 6.09. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.09, ARWR is doing good in the industry, outperforming 64.44% of the companies in the same industry.
A Quick Ratio of 6.09 indicates that ARWR has no problem at all paying its short term obligations.
ARWR has a better Quick ratio (6.09) than 64.96% of its industry peers.
Industry RankSector Rank
Current Ratio 6.09
Quick Ratio 6.09
ARWR Yearly Current Assets VS Current LiabilitesARWR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

ARWR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -86.28%.
Looking at the last year, ARWR shows a very negative growth in Revenue. The Revenue has decreased by -98.62% in the last year.
ARWR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -53.80% yearly.
EPS 1Y (TTM)-86.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.1%
Revenue 1Y (TTM)-98.62%
Revenue growth 3Y-70.5%
Revenue growth 5Y-53.8%
Sales Q2Q%-29.6%

3.2 Future

The Earnings Per Share is expected to grow by 15.17% on average over the next years. This is quite good.
Based on estimates for the next years, ARWR will show a very strong growth in Revenue. The Revenue will grow by 62.19% on average per year.
EPS Next Y25.93%
EPS Next 2Y10.63%
EPS Next 3Y7.52%
EPS Next 5Y15.17%
Revenue Next Year108.16%
Revenue Next 2Y84.9%
Revenue Next 3Y66.72%
Revenue Next 5Y62.19%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ARWR Yearly Revenue VS EstimatesARWR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
ARWR Yearly EPS VS EstimatesARWR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARWR. In the last year negative earnings were reported.
Also next year ARWR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARWR Price Earnings VS Forward Price EarningsARWR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARWR Per share dataARWR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.63%
EPS Next 3Y7.52%

More info and screens

0

5. Dividend

5.1 Amount

ARWR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARROWHEAD PHARMACEUTICALS IN

NASDAQ:ARWR (4/25/2025, 8:00:00 PM)

After market: 13.25 0 (0%)

13.25

-0.09 (-0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10 2025-02-10/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners81.34%
Inst Owner Change0.09%
Ins Owners4.43%
Ins Owner Change6.82%
Market Cap1.82B
Analysts78.1
Price Target45.43 (242.87%)
Short Float %10.04%
Short Ratio6.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-119.78%
Min EPS beat(2)-211.36%
Max EPS beat(2)-28.19%
EPS beat(4)0
Avg EPS beat(4)-225.12%
Min EPS beat(4)-515.69%
Max EPS beat(4)-28.19%
EPS beat(8)1
Avg EPS beat(8)-111.22%
EPS beat(12)2
Avg EPS beat(12)-74.41%
EPS beat(16)2
Avg EPS beat(16)-95.61%
Revenue beat(2)0
Avg Revenue beat(2)-98.32%
Min Revenue beat(2)-100%
Max Revenue beat(2)-96.63%
Revenue beat(4)0
Avg Revenue beat(4)-99.16%
Min Revenue beat(4)-100%
Max Revenue beat(4)-96.63%
Revenue beat(8)1
Avg Revenue beat(8)-50.86%
Revenue beat(12)2
Avg Revenue beat(12)-42.8%
Revenue beat(16)3
Avg Revenue beat(16)-36.85%
PT rev (1m)-2.72%
PT rev (3m)-6.09%
EPS NQ rev (1m)-66.85%
EPS NQ rev (3m)83.6%
EPS NY rev (1m)4.12%
EPS NY rev (3m)-10.71%
Revenue NQ rev (1m)-8.39%
Revenue NQ rev (3m)17.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)27.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 727.8
P/FCF N/A
P/OCF N/A
P/B 34.6
P/tB 40.93
EV/EBITDA N/A
EPS(TTM)-5.16
EYN/A
EPS(NY)-3.89
Fwd EYN/A
FCF(TTM)-4.16
FCFYN/A
OCF(TTM)-3.58
OCFYN/A
SpS0.02
BVpS0.38
TBVpS0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.11%
ROE -1216.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.95%
ROA(5y)-28.18%
ROE(3y)-147.71%
ROE(5y)-99.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 7.75
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 410.53%
Cap/Sales 3213.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.09
Quick Ratio 6.09
Altman-Z -2.81
F-Score2
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)894.03%
Cap/Depr(5y)633.96%
Cap/Sales(3y)1359.68%
Cap/Sales(5y)821.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-86.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.1%
EPS Next Y25.93%
EPS Next 2Y10.63%
EPS Next 3Y7.52%
EPS Next 5Y15.17%
Revenue 1Y (TTM)-98.62%
Revenue growth 3Y-70.5%
Revenue growth 5Y-53.8%
Sales Q2Q%-29.6%
Revenue Next Year108.16%
Revenue Next 2Y84.9%
Revenue Next 3Y66.72%
Revenue Next 5Y62.19%
EBIT growth 1Y-109.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.52%
EBIT Next 3Y3%
EBIT Next 5Y11.01%
FCF growth 1Y-142%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-226.87%
OCF growth 3YN/A
OCF growth 5YN/A